JP6509112B2 - オキソ関連状態の治療、診断および／またはその進行のモニタリングのための方法 - Google Patents

オキソ関連状態の治療、診断および／またはその進行のモニタリングのための方法 Download PDF

Info

Publication number
JP6509112B2
JP6509112B2 JP2015520652A JP2015520652A JP6509112B2 JP 6509112 B2 JP6509112 B2 JP 6509112B2 JP 2015520652 A JP2015520652 A JP 2015520652A JP 2015520652 A JP2015520652 A JP 2015520652A JP 6509112 B2 JP6509112 B2 JP 6509112B2
Authority
JP
Japan
Prior art keywords
thiosulfate
sepsis
administered
composition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015520652A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523364A (ja
JP2015523364A5 (https=
Inventor
プラブダ，ジェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2015523364A publication Critical patent/JP2015523364A/ja
Publication of JP2015523364A5 publication Critical patent/JP2015523364A5/ja
Application granted granted Critical
Publication of JP6509112B2 publication Critical patent/JP6509112B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7004—Stress
    • G01N2800/7009—Oxidative stress
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/20—Oxygen containing
    • Y10T436/206664—Ozone or peroxide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015520652A 2012-07-03 2013-07-02 オキソ関連状態の治療、診断および／またはその進行のモニタリングのための方法 Expired - Fee Related JP6509112B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261667719P 2012-07-03 2012-07-03
US61/667,719 2012-07-03
US201261691787P 2012-08-21 2012-08-21
US61/691,787 2012-08-21
US201361748698P 2013-01-03 2013-01-03
US61/748,698 2013-01-03
PCT/US2013/049087 WO2014008273A2 (en) 2012-07-03 2013-07-02 Methods for treating, diagnosing and/or monitoring progression of oxo associated states

Publications (3)

Publication Number Publication Date
JP2015523364A JP2015523364A (ja) 2015-08-13
JP2015523364A5 JP2015523364A5 (https=) 2016-08-25
JP6509112B2 true JP6509112B2 (ja) 2019-05-08

Family

ID=49882592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015520652A Expired - Fee Related JP6509112B2 (ja) 2012-07-03 2013-07-02 オキソ関連状態の治療、診断および／またはその進行のモニタリングのための方法

Country Status (7)

Country Link
US (1) US20150174160A1 (https=)
EP (1) EP2866565A4 (https=)
JP (1) JP6509112B2 (https=)
CN (1) CN104582490A (https=)
AU (2) AU2013286876B2 (https=)
CA (1) CA2915793A1 (https=)
WO (1) WO2014008273A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522519A (ja) * 2018-04-19 2021-08-30 スティッキーセル ピーティーワイ リミテッドＳｔｉｃｋｙｃｅｌｌ Ｐｔｙ Ｌｔｄ 感染症の技術分野における白血球補充
US11406607B2 (en) 2018-05-24 2022-08-09 University Of Florida Research Foundation, Inc. Compositions, methods of treatment, and containers including compositions
EP4561551A1 (en) * 2022-07-27 2025-06-04 Redox Bioscience LLC Methods and compounds for treating ulcerative colitis, systemic lupus erythematosus, sepsis, and post-sepsis syndrome
US20260086093A1 (en) 2022-09-14 2026-03-26 BiognoSYS AG Methods to determine drug target residence time and to select best drug-target candidates

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309387D0 (en) * 1993-05-06 1993-06-16 Wellcome Found Nitric oxide scavengers
AU682894B2 (en) * 1993-10-28 1997-10-23 Institut National De La Recherche Agronomique Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
US5990153A (en) * 1997-05-05 1999-11-23 Wood; John G. Ultrasonicated α-lipoic acid solutions for attenuating microvascular injury
US6712802B1 (en) * 1997-11-04 2004-03-30 Charles B. Cairns Metabolic therapy directed at electron transport
CN100432049C (zh) * 1998-03-09 2008-11-12 武田药品工业株式会社 环烯衍生物、其制造方法和用途
US20030190368A1 (en) * 1998-03-11 2003-10-09 Roland Stoughton Methods of diagnosis and triage using cell activation measures
FR2791571B1 (fr) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
CN1561218A (zh) * 2001-07-27 2005-01-05 努特里奇亚有限公司 用于预防和/或治疗败血症的肠道组合物
EP1302115A1 (fr) * 2001-10-16 2003-04-16 Societe Des Produits Nestle S.A. Utilisation de cystathionine
DE10151764A1 (de) * 2001-10-19 2003-05-08 Basf Ag Kombination von Liponsäure und Glutamin in Lebens- und Arzneimitteln
CN1675154A (zh) * 2002-06-07 2005-09-28 科蒂科股份有限公司 抑制巨噬细胞移动抑制因子(mif)的细胞因子或生物活性的萘衍生物
US20030235571A1 (en) * 2002-06-19 2003-12-25 Gabriel Gojon-Romanillos Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
US20100112088A1 (en) * 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
US8476233B2 (en) * 2003-08-29 2013-07-02 Therapeutic Research, Llc Methods for treatment for ulcerative colitis in mammals
CA2548313A1 (en) * 2003-12-23 2005-07-14 Musc Foundation For Research Development Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
FR2894482A1 (fr) * 2005-12-14 2007-06-15 Galderma Sa Utilisation d'une composition comprenant une association d'hydroquinone,d'acetonide de fluocinolone et de tretinoine, dans le traitement d'l'hyperpigmentation de la peau suite au psoriasis ou a l'eczema
US9383348B2 (en) * 2008-06-21 2016-07-05 John E. Repine Compositions and methods for treating lung disorders
KR20120110138A (ko) * 2009-12-28 2012-10-09 엔.브이. 페리콘 엘엘씨 국소용 아실 글루타치온 제제

Also Published As

Publication number Publication date
JP2015523364A (ja) 2015-08-13
US20150174160A1 (en) 2015-06-25
CA2915793A1 (en) 2014-01-09
CN104582490A (zh) 2015-04-29
AU2013286876A1 (en) 2015-02-26
AU2017206229A1 (en) 2017-08-03
WO2014008273A3 (en) 2014-02-27
WO2014008273A2 (en) 2014-01-09
AU2013286876B2 (en) 2017-04-20
EP2866565A2 (en) 2015-05-06
EP2866565A4 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
Kolluru et al. Sulfide regulation of cardiovascular function in health and disease
Summar et al. Inborn errors of metabolism with hyperammonemia: urea cycle defects and related disorders
JP5303465B2 (ja) 液体カルコゲナイド組成物ならびにそれを製造および使用する方法
Wiliński et al. Metformin raises hydrogen sulfide tissue concentrations in various mouse organs
CN106822168B (zh) 含硒有机化合物的组合物和其使用方法
JP6509112B2 (ja) オキソ関連状態の治療、診断および／またはその進行のモニタリングのための方法
Rahman et al. The role of host-generated H2S in microbial pathogenesis: new perspectives on tuberculosis
US20120322773A1 (en) Materials and methods for treatment of disorders associated with oxidative stress
JP2009534422A (ja) ショックおよび他の有害な病態を処置するためのカルゴゲニドの使用
Luiking et al. A randomized-controlled trial of arginine infusion in severe sepsis on microcirculation and metabolism
du Preez et al. N‐Acetylcysteine and other sulfur‐donors as a preventative and adjunct therapy for COVID‐19
JPWO2017057768A1 (ja) 新規抗酸化眼内灌流液
Ingelfinger et al. Lactic acidosis
Hohenfellner et al. Beneficial effects of starting oral cysteamine treatment in the first 2 months of life on glomerular and tubular kidney function in infantile nephropathic cystinosis
KR20180034466A (ko) Ado-저항성 시스테아민 유사체 및 그의 용도
Bianchetti et al. Differential diagnosis and management of fluid, electrolyte and acid-base disorders
ES3035910T3 (en) Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis
Grünewald et al. Emergency diagnostic procedures and emergency treatment
CN102014891A (zh) 增加癌症患者存活时间的化合物的组合物和使用方法
Katlan Methylene blue in metformin intoxication: not just rescue but also initial treatment
US20180185443A1 (en) Kit for treating sepsis and/or any systemic (sirs) or damaging cellular hyperinflammation
Chiol├® ro et al. Nutritional support during renal replacement therapy
Huber et al. Photoprotection But Not N‐acetylcysteine Improves Intestinal Blood Flow and Oxidation Status in Parenterally Fed Piglets
Besouw et al. Increased human dermal microvascular endothelial cell survival induced by cysteamine
MD3493849T2 (ro) Utilizare noua a N,N-bis-2-mercaptoetil izoftalamidă

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170321

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190402

R150 Certificate of patent or registration of utility model

Ref document number: 6509112

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees